 | |
| Combination of | |
|---|---|
| Ceftazidime | Cephalosporin antibiotic |
| Avibactam | β-lactamase inhibitor |
| Clinical data | |
| Trade names | Avycaz, Zavicefta, others [1] |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a615018 |
| License data | |
|
Routes of administration | Intravenous infusion |
| Drug class | Antibiotic |
| Legal status | |
| Legal status | |
 
(what is this?) | |
Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. [2] It is used to treat complicated intra abdominal infections, urinary tract infections, and pneumonia. [2] [3] It is only recommended when other options are not appropriate. [2] It is given by injection into a vein. [2]
Common side effect include nausea, fever, liver problems, headache, trouble sleeping, and pain at the site of injection. [2] Severe side effects may include anaphylaxis, seizures, and Clostridium difficile-associated diarrhea. [2] While use appears to be safe in pregnancy the medication has not been well studied in this group. [5] Doses should be adjusted in those with kidney problems. [6] Ceftazidime works by interfering with the building of the bacterial cell wall while avibactam works by preventing ceftazidime's breakdown. [2]
The combination was approved for medical use in the United States and Europe in 2015. [2] [3] It is on the World Health Organization's List of Essential Medicines. [7] In the United States a course of treatment generally costs between US$7,500 to US$15,000 as of 2016. [6] In the United Kingdom this amount costs the NHS about £1,800 to £3,600 as of 2019. [8]
- ^ "Briefing package: ceftazidime-avibactam. Anti-infective drugs advisory committee meeting" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 30 June 2015. Retrieved 27 June 2015.
- ^ a b c d e f g h i j "Ceftazidime and Avibactam Sodium Monograph for Professionals". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
- ^ a b c "Application for inclusion of ceftazidime-avibactam" (PDF). WHO. Archived (PDF) from the original on 28 August 2021. Retrieved 25 October 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 11 September 2020.
- ^ "Avibactam / ceftazidime (Avycaz) Use During Pregnancy". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
- ^
a
b Mosley JF, 2nd; Smith, LL; Parke, CK; Brown, JA; Wilson, AL; Gibbs, LV (August 2016).
"Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections". Pharmacy and Therapeutics. 41 (8): 479–83.
PMC
4959616.
PMID
27504064.
{{ cite journal}}: CS1 maint: numeric names: authors list ( link) - ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. X. ISBN 9780857113382.
|
| |
| Combination of | |
|---|---|
| Ceftazidime | Cephalosporin antibiotic |
| Avibactam | β-lactamase inhibitor |
| Clinical data | |
| Trade names | Avycaz, Zavicefta, others [1] |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a615018 |
| License data | |
|
Routes of administration | Intravenous infusion |
| Drug class | Antibiotic |
| Legal status | |
| Legal status | |
|
(what is this?) | |
Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. [2] It is used to treat complicated intra abdominal infections, urinary tract infections, and pneumonia. [2] [3] It is only recommended when other options are not appropriate. [2] It is given by injection into a vein. [2]
Common side effect include nausea, fever, liver problems, headache, trouble sleeping, and pain at the site of injection. [2] Severe side effects may include anaphylaxis, seizures, and Clostridium difficile-associated diarrhea. [2] While use appears to be safe in pregnancy the medication has not been well studied in this group. [5] Doses should be adjusted in those with kidney problems. [6] Ceftazidime works by interfering with the building of the bacterial cell wall while avibactam works by preventing ceftazidime's breakdown. [2]
The combination was approved for medical use in the United States and Europe in 2015. [2] [3] It is on the World Health Organization's List of Essential Medicines. [7] In the United States a course of treatment generally costs between US$7,500 to US$15,000 as of 2016. [6] In the United Kingdom this amount costs the NHS about £1,800 to £3,600 as of 2019. [8]
- ^ "Briefing package: ceftazidime-avibactam. Anti-infective drugs advisory committee meeting" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 30 June 2015. Retrieved 27 June 2015.
- ^ a b c d e f g h i j "Ceftazidime and Avibactam Sodium Monograph for Professionals". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
- ^ a b c "Application for inclusion of ceftazidime-avibactam" (PDF). WHO. Archived (PDF) from the original on 28 August 2021. Retrieved 25 October 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 11 September 2020.
- ^ "Avibactam / ceftazidime (Avycaz) Use During Pregnancy". Drugs.com. Archived from the original on 25 October 2019. Retrieved 25 October 2019.
- ^
a
b Mosley JF, 2nd; Smith, LL; Parke, CK; Brown, JA; Wilson, AL; Gibbs, LV (August 2016).
"Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections". Pharmacy and Therapeutics. 41 (8): 479–83.
PMC
4959616.
PMID
27504064.
{{ cite journal}}: CS1 maint: numeric names: authors list ( link) - ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. X. ISBN 9780857113382.